E Kantorová1, H Poláček2, M Bittšanský3, E Baranovičová3, P Hnilicová3, D Čierny4, Š Sivák1, V Nosáľ1, K Zeleňák5, E Kurča1. 1. a Clinic of Neurology, Jessenius Faculty of Medicine in Martin , Comenius University Bratislava , Slovakia. 2. b Clinic of Nuclear Medicine, Jessenius Faculty of Medicine in Martin , Comenius University Bratislava , Bratislava , Slovakia. 3. c BioMed Division of Neurosciences, Biomedical Center Martin, Jessenius Faculty of Medicine in Martin , Comenius University Bratislava , Bratislava , Slovakia. 4. d Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin , Comenius University Bratislava , Bratislava , Slovakia. 5. e Clinic of Radiodiagnostics, Jessenius Faculty of Medicine in Martin , Comenius University Bratislava , Bratislava , Slovakia.
Abstract
OBJECTIVES: Disturbances in the hypothalamo-pituitary axis are supposed to modulate activity of multiple sclerosis (MS). We hypothesised that the extent of HYP damage may determine severity of MS and may be associated with the disease evolution. We suggested fatigue and depression may depend on the degree of damage of the area. METHOD: 33 MS patients with relapsing-remitting and secondary progressive disease, and 24 age and sex-related healthy individuals (CON) underwent 1H-MR spectroscopy (1H-MRS) of the hypothalamus. Concentrations of glutamate + glutamin (Glx), cholin (Cho), myoinositol (mIns), N-acetyl aspartate (NAA) expressed as ratio with creatine (Cr) and NAA were correlated with markers of disease activity (RIO score), Multiple Sclerosis Severity Scale (MSSS), Depressive-Severity Status Scale and Simple Numerical Fatigue Scale. RESULTS: Cho/Cr and NAA/Cr ratios were decreased and Glx/NAA ratio increased in MS patients vs CON. Glx/NAA, Glx/Cr, and mIns/NAA were significantly higher in active (RIO 1-2) vs non-active MS patients (RIO 0). Glx/NAA and Glx/Cr correlated with MSSS and fatigue score, and Glx/Cr with depressive score of MS patients. In CON, relationships between Glx/Cr and age, and Glx/NAA and fatigue score were inverse. CONCLUSION: Our study provides the first evidence about significant hypothalamic alterations correlating with clinical outcomes of MS, using 1H-MRS. The combination of increased Glu or mIns with reduced NAA in HYP reflects whole-brain activity of MS. In addition, excess of Glu is linked to severe disease course, depressive mood and fatigue in MS patients, suggesting superiority of Glu over other metabolites in determining MS burden.
OBJECTIVES: Disturbances in the hypothalamo-pituitary axis are supposed to modulate activity of multiple sclerosis (MS). We hypothesised that the extent of HYP damage may determine severity of MS and may be associated with the disease evolution. We suggested fatigue and depression may depend on the degree of damage of the area. METHOD: 33 MSpatients with relapsing-remitting and secondary progressive disease, and 24 age and sex-related healthy individuals (CON) underwent 1H-MR spectroscopy (1H-MRS) of the hypothalamus. Concentrations of glutamate + glutamin (Glx), cholin (Cho), myoinositol (mIns), N-acetyl aspartate (NAA) expressed as ratio with creatine (Cr) and NAA were correlated with markers of disease activity (RIO score), Multiple Sclerosis Severity Scale (MSSS), Depressive-Severity Status Scale and Simple Numerical Fatigue Scale. RESULTS:Cho/Cr and NAA/Cr ratios were decreased and Glx/NAA ratio increased in MSpatients vs CON. Glx/NAA, Glx/Cr, and mIns/NAA were significantly higher in active (RIO 1-2) vs non-active MSpatients (RIO 0). Glx/NAA and Glx/Cr correlated with MSSS and fatigue score, and Glx/Cr with depressive score of MSpatients. In CON, relationships between Glx/Cr and age, and Glx/NAA and fatigue score were inverse. CONCLUSION: Our study provides the first evidence about significant hypothalamic alterations correlating with clinical outcomes of MS, using 1H-MRS. The combination of increased Glu or mIns with reduced NAA in HYP reflects whole-brain activity of MS. In addition, excess of Glu is linked to severe disease course, depressive mood and fatigue in MSpatients, suggesting superiority of Glu over other metabolites in determining MS burden.
Authors: Charles P Lewis; John D Port; Caren J Blacker; A Irem Sonmez; Bhedita J Seewoo; Jarrod M Leffler; Mark A Frye; Paul E Croarkin Journal: Transl Psychiatry Date: 2020-04-23 Impact factor: 6.222
Authors: Louise Martens; Luisa Herrmann; Lejla Colic; Meng Li; Anni Richter; Gusalija Behnisch; Oliver Stork; Constanze Seidenbecher; Björn H Schott; Martin Walter Journal: Sci Rep Date: 2021-03-24 Impact factor: 4.379
Authors: Young Woo Park; Dinesh K Deelchand; James M Joers; Anjali Kumar; Alison Bunio Alvear; Amir Moheet; Elizabeth R Seaquist; Gülin Öz Journal: Front Neurol Date: 2021-08-18 Impact factor: 4.003
Authors: Petra Hnilicová; Oliver Štrbák; Martin Kolisek; Egon Kurča; Kamil Zeleňák; Štefan Sivák; Ema Kantorová Journal: Int J Mol Sci Date: 2020-08-25 Impact factor: 5.923